Trial Profile
An Open-Label Phase I Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate (E7389) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Rifampicin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Eisai Co Ltd
- 27 Dec 2016 New trial record